Non Small Cell Lung Cancer - osimertinib - EGFR mutation + TP53 mutation + ARID1A mutation

Association details:

Biomarker:	EGFR mutation + TP53 mutation + ARID1A mutation
Cancer:	Non Small Cell Lung Cancer
Drug:	Tagrisso (osimertinib) (EGFR inhibitor)
Direction:	Resistant

Evidence:

Evidence Level:

Resistant: C3 – Early Trials

Source:

J Thorac Oncol

Title:

Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer

Published date:

10/05/2023

Excerpt:

Patients with EGFR-mutant NSCLC treated with EGFR-TKIs who had tumor genomic profiling were included. Alterations in TP53 and five additional TSGs (RB1, NF1, ARID1A, BRCA1 and PTEN) were used to stratify the cohort into three subgroups: patients with tumors harboring a TP53 mutation plus a mutation in ≥1 additional TSG (TP53mut/TSGmut), a TP53 mutation without additional TSG mutations (TP53mut/TSGwt), and TP53wt....Inferior outcomes in TP53mut/TSGmut tumors were also seen in patients receiving osimertinib as second-line therapy.

DOI:

https://doi.org/10.1016/j.jtho.2023.10.001